IP Library Granted Patent US 8,541,446
Granted Patent B2
US 8,541,446 · App. 13/116,080 · Granted Sep 24, 2013

(2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofurn-2-carboxamide, novel salt forms, and methods of use thereof

Inventors: Merouane Bencherif (Winston-Salem, NC); Lisa Benson (Kernersville, NC); Gary Maurice Dull (Lewisville, NC); Nikolai Fedorov (Winston-Salem, NC); Gregory J. Gatto (Winston-Salem, NC); Kristen G. Jordan (Clemmons, NC); Anatoly A. Mazurov (Greensboro, NC); Lan Miao (Advance, NC); Julio A. Munoz (Walnut Cove, NC); Inigo Pfeiffer (Kernersville, NC); Sondra Pfeiffer (Kernersville, NC); Teresa Phillips (Greensboro, NC)
Assignee: Targacept, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,446
App. No.
13/116,080
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.

Claims (3)

1. A compound (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, substantially free of (2S,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, (2R,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, (2R,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, and pharmaceutically acceptable salts thereof.

2. A method for treating schizophrenia or cognitive dysfunction in schizophrenia comprising administering to a subject in need thereof the compound of claim 1 .

3. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable diluent, excipient, or carrier.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2025
From: CODA BIOTHERAPEUTICS, INC
To: CODA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 072176/0524 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2025
From: CODA (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: TRAMES BIO, INC.
Reel/Frame 072176/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2025
From: ATTENUA, INC.
To: CODA BIOTHERAPEUTIES, INC.
Reel/Frame 072176/0358 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2024
From: CODA BIOTHERAPEUTICS, INC.
To: TRAMES BIO, INC.
Reel/Frame 067341/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2024
From: BENCHERIF, MAROUANE; BENSON, LISA; DULL, GARY MAURICE; FEDOROV, NIKOLAI; GATTO, GREGORY J.; JORDAN, KRISTEN G.; MAZUROV, ANATOLY A.; MIAO, LAN; MUNOZ, JULIO A.; PFEIFFER, INIGO; PFEIFFER, SONDRA; PHILLIPS, TERESA Y.
To: TARGACEPT, INC.
Reel/Frame 067230/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2016
From: CATALYST BIOSCIENCES, INC.
To: ATTENUA, INC.
Reel/Frame 039688/0771 →
CHANGE OF NAME Recorded Aug 11, 2016
From: TARGACEPT , INC.
To: CATALYST BIOSCIENCES, INC.
Reel/Frame 039646/0595 →
Continuity (6)
Continuation 12184312 · Aug 1, 2008
Provisional Application 60971654 · Sep 12, 2007
Provisional Application 60953610 · Aug 2, 2007
Provisional Application 60953613 · Aug 2, 2007
Provisional Application 60953614 · Aug 2, 2007
Related Publication 20120129885A1 · May 24, 2012